Put companies on watchlist
European Healthcare Acquisition & Growth Company B.V.
ISIN: NL0015000K10
WKN: A3C60V
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

European Healthcare Acquisition & Growth Company B.V. · ISIN: NL0015000K10 · EQS - Company News (44 News)
Country: Germany · Primary market: Netherlands · EQS NID: 1592291
24 March 2023 06:50PM

European Healthcare Acquisition & Growth Company B.V. publishes its Annual Report 2022


EQS-News: European Healthcare Acquisition & Growth Company B.V. / Key word(s): Annual Report
European Healthcare Acquisition & Growth Company B.V. publishes its Annual Report 2022 (news with additional features)

24.03.2023 / 18:50 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

European Healthcare Acquisition & Growth Company B.V.  publishes its annual report for the financial year 2022 

Amsterdam, 24 March 2023

Today, European Healthcare Acquisition & Growth Company B.V. ("EHC"), a Dutch operators-led special purpose acquisition company listed on Euronext Amsterdam that announced on 22 December 2022 that it signed a business combination agreement with Austrian-based Croma-Pharma GmbH, publishes its annual report for the financial year 2022 (the "Annual Report 2022"), including its financial statements and the report of its board.

The Annual Report 2022 relates to the financial year 2022, from 1 January 2022 to 31 December 2022, a period prior to completion of the proposed business combination of EHC with Croma-Pharma GmbH. The business combination is expected to complete in the second half of Q2 2023. The Annual Report 2022 therefore does not comprise any accounts or results of Croma-Pharma GmbH.

The Annual Report 2022 can be downloaded from the website of EHC in the 'Investor Relations' section under 'News & Publications': www.ehc-company.com, where a downloadable version in the European Single Electronic Format (ESEF) is also available.

The annual general meeting of shareholders of EHC will be held during the second half of Q2 2023, at which the Annual Report 2022 will be discussed and the shareholders of EHC will vote on the proposed business combination with Croma-Pharma GmbH. The agenda of the AGM as well as a shareholder circular containing information on the business combination will be published in due course. Croma-Pharma GmbH is expected to publish its 2022 audited financial statements in the coming weeks.

European Healthcare Acquisition & Growth Company B.V.

 

General Enquiries

+49 (0) 89 4523240

info@ehc-company.com

 

Media Enquiries

FGS Global

Kai Peter Rath

+49 211 43079-209

kai.rath@fgsglobal.com

 

Disclaimer

This press release, and the Annual Report 2022, may include forward-looking statements, which are based on EHC's current expectations and projections about future events and speak only as of the date hereof. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors because they relate to events and depend on circumstances that will occur in the future whether or not within or outside the control of EHC. Such factors may cause actual results, performance or developments to differ materially from those expressed or implied by such forward-looking statements. Accordingly, no undue reliance should be placed on any forward-looking statements. EHC operates in a rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor to assess the impact that these factors will have on EHC. Forward-looking statements speak only as at the date at which they are made and EHC undertakes no obligation to update these forward-looking statements. Further reference is made to the risk factors in the Annual Report 2022.

This press release contains information that may qualify as inside information within the meaning of Article 7, paragraph 1, of the EU Market Abuse Regulation.
 


Additional features:

File: European Healthcare Acquisition & Growth Company B.V. publishes its Annual Report 2022


24.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: European Healthcare Acquisition & Growth Company B.V.
c/o ALR Treuhand GmbH; Theresienhöhe 28
80339 München
Germany
ISIN: NL0015000K10, NL0015000K28
WKN: A3C60V
Listed: Regulated Unofficial Market in Frankfurt, Munich, Stuttgart; Amsterdam
EQS News ID: 1592291

 
End of News EQS News Service

1592291  24.03.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1592291&application_name=news&site_id=boersengefluester_html
Visual performance / price development - European Healthcare Acquisition & Growth Company B.V.
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.